EUCTR2009-014299-22-NL进行中（未招募）不适用
Can dipyridamole induce protection against ischemia and reperfusion injury in patients undergoing elective CABG?
RUNMC0 个研究点开始时间: 2009年7月17日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Acceptation for CABG in RUNMC
- •- Informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-Recent myocardial infarction (STEMI or non-STEMI), during two weeks prior to inclusion
- •-Use of insulin
- •- Use of sulfonylurea derivates (e.g. glibenclamide, tolbutamide, gliclazide,
- •glimepiride)
- •- Use of metformin
- •- Use of oral corticosteroids
- •- Use of dipyridamole
- •- Use of clopidogrel within 8 days prior to scheduled CABG surgery
- •- Chronic use of Non Steroid Anti-Inflammatory Drugs (NSAIDs)
- •- Chronic or paroxysmal atrial fibrillation
- •- Right ventricular failure
研究者
相似试验
已完成
4 期
Can dipyridamole induce protection against ischemia and reperfusion injury in patients undergoing elective CABG?heart attackischemia reperfusion injury10011082NL-OMON33210niversitair Medisch Centrum Sint Radboud130
已完成
4 期
Can Dipyridamole Induce Protection Against Ischemia and Reperfusion Injury in Patients Undergoing Elective Coronary Artery Bypass Grafting (CABG)?Ischemic Heart DiseaseCardiovascular DiseaseNCT01295567Radboud University Medical Center95
进行中（未招募）
1 期
The effect of dipyridamole on the pharmacokinetics of metformin.The antihyperglycemic drug metformin and the thrombocyte aggregation inhibitor dipyridamole are often used concomitantly in patients with diabetes who have suffered a transient ischemic attack or stroke. Gastrointestinal absorption of metformin is mediated by the equilibrative nucleoside transporter 4 (hENT4). Dipyridamole has been reported to inhibit hENT4 transport in vitro. Dipyridamole may therefore negatively influence the uptake of metformin from the gastrointestinal tract.MedDRA version: 14.1Level: PTClassification code 10068071Term: Inhibitory drug interactionSystem Organ Class: 10018065 - General disorders and administration site conditionsMedDRA version: 14.1Level: PTClassification code 10013710Term: Drug interactionSystem Organ Class: 10018065 - General disorders and administration site conditionsEUCTR2012-000363-24-NLRadboud University Medical Centre Nijmegen18
招募中
4 期
The effect of dipyridamole on the pharmacokinetics of metformin.geneesmiddeleninteractieDrug interactionNL-OMON37582niversitair Medisch Centrum Sint Radboud18
尚未招募
4 期
Does short dipyridamole administration induce protection against ischemia-reperfusion injury?infarctionischemia reperfusion injury1001108210003216NL-OMON31190niversitair Medisch Centrum Sint Radboud10